Four companies have brought noninvasive prenatal testing to the market within the past two years. Its dramatic, rapid uptake has triggered a backlash among many geneticists, who fear the consequences of a poorly understood – and overhyped – technology.
Since the commercial introduction of Sequenom Inc.’s MaterniT21 test in October 2011, noninvasive prenatal testing (NIPT) has become the hottest – and most controversial – area of clinical genomics.
The drive toward NIPT was rooted in the bold dream of replacing invasive diagnostic testing for genetic disorders, which entails...
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
